The interplay between the PPAR pathway and chemoresistance has garnered attention across diverse cancers, including diffuse large B-cell lymphoma (DLBCL) (44), breast cancer (45), hepatocellular carcinoma (HCC) (46), non-small cell lung cancer (NSCLC) (47), and OC (48). Here, PPARA is linked to diffuse large B-cell lymphoma.